Fidelity Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Fidelity Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,029,557	Closed	-$740M	–	5373
2021 Q2	$740M	Buy	4,029,557 +501,470	+14%	+$86.1M	0.06%	310
2021 Q1	$539M	Sell	3,528,087 -2,756,438	-44%	-$426M	0.05%	408
2020 Q4	$982M	Sell	6,284,525 -3,507,922	-36%	-$451M	0.09%	211
2020 Q3	$1.12B	Sell	9,792,447 -3,208,004	-25%	-$346M	0.11%	159
2020 Q2	$1.46B	Buy	13,000,451 +1,117,179	+9%	+$119M	0.16%	114
2020 Q1	$1.07B	Sell	11,883,272 -2,809,110	-19%	-$276M	0.15%	127
2019 Q4	$1.59B	Sell	14,692,382 -4,902,148	-25%	-$524M	0.18%	108
2019 Q3	$1.92B	Sell	19,594,530 -5,991,461	-23%	-$675M	0.23%	80
2019 Q2	$3.35B	Sell	25,585,991 -3,558,329	-12%	-$459M	0.39%	39
2019 Q1	$3.94B	Buy	29,144,320 +2,746,055	+10%	+$341M	0.47%	32
2018 Q4	$2.57B	Buy	26,398,265 +5,301,272	+25%	+$627M	0.35%	48
2018 Q3	$2.93B	Buy	21,096,993 +1,581,376	+8%	+$198M	0.33%	45
2018 Q2	$2.42B	Buy	19,515,617 +225,688	+1%	+$26.4M	0.28%	54
2018 Q1	$2.15B	Buy	19,289,929 +1,615,805	+9%	+$193M	0.26%	66
2017 Q4	$2.11B	Sell	17,674,124 -1,284,809	-7%	-$156M	0.25%	71
2017 Q3	$2.66B	Sell	18,958,933 -2,415,344	-11%	-$328M	0.32%	51
2017 Q2	$2.6B	Sell	21,374,277 -5,627,122	-21%	-$655M	0.32%	51
2017 Q1	$3.27B	Sell	27,001,399 -1,166,764	-4%	-$150M	0.42%	36
2016 Q4	$3.45B	Buy	28,168,163 +3,338,382	+13%	+$408M	0.46%	33
2016 Q3	$3.04B	Buy	24,829,781 +6,083,986	+32%	+$783M	0.41%	42
2016 Q2	$2.19B	Buy	18,745,795 +2,002,085	+12%	+$284M	0.3%	63
2016 Q1	$2.33B	Buy	16,743,710 +1,864,885	+13%	+$274M	0.32%	56
2015 Q4	$2.84B	Buy	14,878,825 +358,224	+2%	+$62.6M	0.38%	43
2015 Q3	$2.27B	Sell	14,520,601 -419,401	-3%	-$76.5M	0.32%	50
2015 Q2	$2.7B	Sell	14,940,002 -4,736,915	-24%	-$817M	0.35%	50
2015 Q1	$3.41B	Sell	19,676,917 -2,468,340	-11%	-$447M	0.43%	37
2014 Q4	$4.1B	Buy	22,145,257 +2,043,255	+10%	+$379M	0.53%	28
2014 Q3	$3.33B	Buy	20,102,002 +2,392,465	+14%	+$393M	0.45%	37
2014 Q2	$2.77B	Sell	17,709,537 -2,971,616	-14%	-$469M	0.37%	47
2014 Q1	$3.15B	Buy	20,681,153 +1,113,004	+6%	+$177M	0.44%	39
2013 Q4	$2.6B	Sell	19,568,149 -372,199	-2%	-$44.7M	0.37%	51
2013 Q3	$2.32B	Buy	19,940,348 +3,157,520	+19%	+$346M	0.35%	52
2013 Q2	$1.55B	Buy	+16,782,828	New	+$1.62B	0.25%	76

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Fidelity Investments's ALXN Position: Q3 2021 in Review

Fidelity Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,029,557 shares — an estimated $740M sold.

Fidelity Investments first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $4.1B in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Fidelity Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Fidelity Investments sold 4,029,557 Alexion Pharmaceuticals shares in Q3 2021, an estimated $740M.
Fidelity Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Fidelity Investments's Alexion Pharmaceuticals position peaked at $4.1B in Q4 2014.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Fidelity Investments's 13F filing for Q3 2021, filed 15 Nov 2021.